Icodextrin dialysate improves nutritional and inflammatory profiles in peritoneal dialysis patients

Renal Failure

Volumn 31, Issue 2, 2009, Pages 98-105

  Lin, Wei ^a   Chen, Yung Chih ^b   Wu, Mai Szu ^b   Hsu, Heng Jung ^b   Sun, Chiao Yin ^b   Lin, Ying Kuang ^b   Wu, I Wen ^b  

^a KUO GENERAL HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Icodextrin; Inflammation; Nutrition; Peritoneal dialysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BICARBONATE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CALCIUM PHOSPHATE; CHOLESTEROL; CREATININE; EXTRANEAL; FERRITIN; GLUCOSE; HEMOGLOBIN; ICODEXTRIN; PARATHYROID HORMONE; PHOSPHORUS; POTASSIUM; SODIUM; TRANSFERRIN; TRIACYLGLYCEROL; UREA; URIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CALCIUM BLOOD LEVEL; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSATE; DISEASE MARKER; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; FLUID BALANCE; HEMATOCRIT; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFLAMMATION; KIDNEY FUNCTION; MALE; NUTRITIONAL STATUS; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN DEGRADATION; RETROSPECTIVE STUDY; SODIUM BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAFILTRATION; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADULT; AGED; C-REACTIVE PROTEIN; DIALYSIS SOLUTIONS; FEMALE; GLUCANS; GLUCOSE; HEMODIAFILTRATION; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NUTRITIONAL STATUS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RETROSPECTIVE STUDIES; WATER-ELECTROLYTE BALANCE;

EID: 61649089516     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802595500     Document Type: Article

References (37)

1. Wiggins KJ, Rumpsfeld M, Blizzard S, Johnson DW. Predictors of a favourable response to icodextrin in peritoneal dialysis patients with ultrafiltration failure. Nephrology (Carlton). Feb 2005;10(1):33-36.
2. Wolfson M, Ogrinc F, Mujais S. Review of clinical trial experience with icodextrin. Kidney Int Suppl. Oct 2002(81):S46-S52.
3. Amici G, Da Rin G, Agostini A, Velo S, Bocci C. Ten years after MIDAS: Icodextrin lights and shadows. Contrib Nephrol. 2003(140):76-81.
4. Gursu EM, Ozdemir A, Yalinbas B, et al. The effect of icodextrin and glucose-containing solutions on insulin resistance in CAPD patients. Clin Nephrol. Oct 2006;66(4):263-268.
5. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol. Jul 2001;12(7):1549-1557.
6. Wu MS, Lin CL, Chang CT, Wu CH, Huang JY, Yang CW. Improvement in clinical outcome by early nephrology referral in type II diabetics on maintenance peritoneal dialysis. Perit Dial Int. Jan-Feb 2003;23(1):39-45.
7. Wang T, Heimburger O, Bergstrom J, Lindholm B. Nutritional problems in peritoneal dialysis: An overview. Perit Dial Int. 1999;19 (Suppl. 2):S297-S303.
8. Twardowski ZJ, Nolph KD, Khanna R, et al. Peritoneal equilibration test. Peritoneal Dialysis Bulletin. 1987;7(3):138-147.
9. Katzarski K, Charra B, Laurent G, et al. Multifrequency bioimpedance in assessment of dry weight in hemodialysis. Nephrol Dial Transplant. 1996;11 (Suppl.) 2:20-23.
10. Kopple JD, Jones MR, Keshaviah PR, et al. A proposed glossary for dialysis kinetics. Am J Kidney Dis. 1995;26(6):963-981.
11. Cheng LT, Tang W, Wang T. Strong association between volume status and nutritional status in peritoneal dialysis patients. Am J Kidney Dis. 2005;45(5):891-902.
12. Aguilera A, Codoceo R, Selgas R, et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: Their relationship with nutritional parameters. Nephrol Dial Transplant. Jun 1998;13(6):1476-1483.
13. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet. 1999;353(9167):1838-1842.
14. Mitch WE. Malnutrition: A frequent misdiagnosis for hemodialysis patients. J Clin Invest. 2002;110(4):437-439.
15. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996;335(25):1897-1905.
16. Chung SH, Heimburger O, Stenvinkel P, Wang T, Lindholm B. Influence of peritoneal transport rate, inflammation, and fluid removal on nutritional status and clinical outcome in prevalent peritoneal dialysis patients. Perit Dial Int. 2003;23(2):174-183.
17. Selim G, Stojceva-Taneva O, Zafirovska K, et al. Inflammation predicts all-cause and cardiovascular mortality in hemodialysis patients. Prilozi. 2006;27(1):133-144.
18. Stenvinkel P. Leptin and its clinical implications in chronic renal failure. Miner Electrolyte Metab. 1999;25(4-6):298-302.
19. Rahmouni K, Haynes WG. Leptin and the cardiovascular system. Recent Prog Horm Res. 2004;59:225-244.
20. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol. 1998;9(6):1080-1084.
21. Vignioble M, Brichard S, Jadoul M, Goffin E. Serum leptin concentration in peritoneal dialysis patients: Determinants, longitudinal evolution and circadian rhythm. Acta Clin Belg. 2001;56(3):173-179.
22. Opatrna S, Racek J, Stehlik P, et al. [Effect of a dialysis solution with icodextrin on ultrafiltration and selected metabolic parameters in patients treated with peritoneal dialysis.] Cas Lek Cesk. 2002;141(9):281-285.
23. Wu CH, Huang CC, Huang JY, Wu MS, Leu ML. High flux peritoneal membrane is a risk factor in survival of CAPD treatment. Adv Perit Dial. 1996;12:105-109.
24. Posthuma N, ter Wee PM, Donker AJ, Oe PL, Peers EM, Verbrugh HA. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int. 2000;20 (Suppl. 2):S106-S113.
25. Wolfson M, Piraino B, Hamburger RJ, Morton AR. A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis. 2002 Nov;40(5):1055-1065.
26. Finkelstein F, Healy H, Abu-Alfa A, Ahmad S, Brown F, Gehr T, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol. 2005 Feb;16(2):546-554.
27. Davies SJ, Woodrow G, Donovan K, Plum J, Williams P, Johansson AC, et al. Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial. J Am Soc Nephrol. 2003 Sep;14(9):2338-2344.
28. Woodrow G, Oldroyd B, Stables G, Gibson J, Turney JH, Brownjohn AM. Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis. Nephrol Dial Transplant. 2000 Jun;15(6):862-866.
29. Davies SJ. Exploring new evidence of the clinical benefits of icodextrin solutions. Nephrol Dial Transplant. 2006 Jul;21 (Suppl. 2):ii47-ii50.
30. le Poole CY, Welten AG, Weijmer MC, Valentijn RM, van Ittersum FJ, ter Wee PM. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int. 2005 Feb;25 (Suppl. 3):S64-S68.
31. Konings CJ, Kooman JP, Schonck M, Gladziwa U, Wirtz J, van den Wall Bake AW, et al. Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney International. 2003 Apr;63(4):1556-1563.
32. Dumler F. Hypoalbuminemia is a marker of overhydration in chronic maintenance patients on dialysis. Asaio J. 2003 May-Jun;49(3):282-286.
33. Wang AY, Sanderson J, Sea MM, Wang M, Lam CW, Li PK, et al. Important factors other than dialysis adequacy associated with inadequate dietary protein and energy intakes in patients receiving maintenance peritoneal dialysis. The American Journal of Clinical Nutrition. 2003 Apr;77(4):834-841.
34. Jones CH, Wells L, Stoves J, Farquhar F, Woodrow G. Can a reduction in extracellular fluid volume result in increased serum albumin in peritoneal dialysis patients? Am J Kidney Dis. 2002 Apr;39(4):872-875.
35. Freeman LM, Roubenoff R. The nutrition implications of cardiac cachexia. Nutrition Reviews. 1994 Oct;52(10):340-347.
36. Fantino M, Wieteska L. Evidence for a direct central anorectic effect of tumor-necrosis-factor-alpha in the rat. Physiology & Behavior. 1993 Mar;53(3):477-483.
37. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. The Journal of Clinical Investigation. 1997 Dec 1;100(11):2777-2782.